ME02230B - Inhibitori fosfoinozitid 3-kinaze sa delom koji vezuje cink - Google Patents

Inhibitori fosfoinozitid 3-kinaze sa delom koji vezuje cink

Info

Publication number
ME02230B
ME02230B MEP-2015-149A MEP14915A ME02230B ME 02230 B ME02230 B ME 02230B ME P14915 A MEP14915 A ME P14915A ME 02230 B ME02230 B ME 02230B
Authority
ME
Montenegro
Prior art keywords
heteroaryl
aryl
aliphatic
acyl
heterocyclic
Prior art date
Application number
MEP-2015-149A
Other languages
English (en)
Inventor
Xiong Cai
Haixiao Zhai
Cheng-Jung Lai
Changgeng Qian
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Publication of ME02230B publication Critical patent/ME02230B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (1)

1. Jedinjenje koje je predstavljeno formulom (IV), (V), (VI) ili (VII); ili njegova farmaceutski prihvatljiva so, gde ---------- predstavlja jednostruku ili dvostruku vezu; B je prav ili razgranati, alkil, alkenil, alkinil, arilalkil, arilalkenil, arilalkinil, heteroarilalkil, heteroarilalkenil, heteroarilalkinil, heterociklilalkil, heterociklilalkenil, heterociklilalkinil, aril, heteroaril, heterociklil, cikloalkil, cikloalkenil, alkilarilalkil, alkilarilalkenil, alkilarilalkinil, alkenilarilalkil, alkenilarilalkenil, alkenilarilalkinil, alkinilarilalkil, alkinilarilalkenil, alkinilarilalkinil, alkilheteroarilalkil, alkilheteroarilalkenil, alkilheteroarilalkinil, alkenilheteroarilalkil, alkenilheteroarilalkenil, alkenilheteroarilalkinil, alkinilheteroarilalkil, alkinilheteroarilalkenil, alkinilheteroarilalkinil, alkilheterociklilalkil, alkilheterociklilalkenil, alkilheterociklilalkinil, alkenilheterociklilalkil, alkenilheterociklilalkenil, alkenilheterociklilalkinil, alkinilheterociklilalkil, alkinilheterociklilalkenil, alkinilheterociklilalkinil, alkilaril, alkenilaril, alkinilaril, alkilheteroaril, alkenilheteroaril, ili alkinilheteroaril, kod kog jedan ili više metilena može da se prekine ili završi putem O, S, S(O), SO2, N(R8), C(O), arila, heteroarila, ili heterocillika;s je 1; q i r su svaki 0; n je 0, 1, 2, 3 ili 4; p je 0, 1 ili 2; G1 je CHR1, S, O, NR10 ili NS(O)2R10;G2 je supstituisani ili nesupstituisani arili ili supstituisani ili nesupstituisani heteroaril; svaki R1 i R2 se nezavisno bira iz hidroksi, amino, halogen, alkoksi, alkilamino, dialkilamino, CF3, CN, NO2, sulfonil, acil, alifatik, aril, heteroaril i heterociklik;svaki R8 je nezavisno vodonik, acili ili alifatik; R10 se bira iz vodonika, hidroksi, amino, alkoksi, alkilamino, dialkilamino, sulfonil, acil, alifatik, aril, heteroaril, i heterociklik;m je 0, 1, 2 ili 3; G4 je S ili O;svaki R3 je nezavisno izabran iz hidroksi, amino, halogen, alkoksi, alkilamino, dialkilamino, CF3, CN, NO2, sulfonil, acil, alifatik, supstituisani alifatik, aril, heteroaril, i heterociklik; i Cis gde se R33 bira iz vodonika i C1-C8 alkila.
MEP-2015-149A 2009-01-08 2010-01-08 Inhibitori fosfoinozitid 3-kinaze sa delom koji vezuje cink ME02230B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14327109P 2009-01-08 2009-01-08
US17258009P 2009-04-24 2009-04-24
EP10729566.9A EP2385832B1 (en) 2009-01-08 2010-01-08 Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
PCT/US2010/020495 WO2010080996A1 (en) 2009-01-08 2010-01-08 Phosphoinositide 3-kinase inhibitors with a zinc binding moiety

Publications (1)

Publication Number Publication Date
ME02230B true ME02230B (me) 2016-02-20

Family

ID=42316830

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2015-149A ME02230B (me) 2009-01-08 2010-01-08 Inhibitori fosfoinozitid 3-kinaze sa delom koji vezuje cink

Country Status (25)

Country Link
US (11) US8367663B2 (me)
EP (1) EP2385832B1 (me)
JP (3) JP5452617B2 (me)
KR (2) KR101430424B1 (me)
CN (1) CN102341108B (me)
AU (1) AU2010203512C1 (me)
BR (1) BRPI1004899B8 (me)
CA (1) CA2749228C (me)
CY (1) CY1116797T1 (me)
DK (1) DK2385832T3 (me)
EA (1) EA024252B1 (me)
ES (1) ES2550032T3 (me)
HR (1) HRP20150947T1 (me)
HU (1) HUE027615T2 (me)
IL (2) IL213976A (me)
ME (1) ME02230B (me)
MX (1) MX2011007326A (me)
PL (1) PL2385832T3 (me)
PT (1) PT2385832E (me)
RS (1) RS54230B1 (me)
SG (2) SG196815A1 (me)
SI (1) SI2385832T1 (me)
SM (1) SMT201500226B (me)
TW (1) TWI558710B (me)
WO (1) WO2010080996A1 (me)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010203512C1 (en) 2009-01-08 2013-10-17 Curis, Inc. Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
EP2475375A4 (en) * 2009-09-09 2013-02-20 Avila Therapeutics Inc PI3 KINASE INHIBITORS AND USES THEREOF
AU2011239537A1 (en) * 2010-04-16 2012-11-15 Curis, Inc. Treatment of cancers having K-ras mutations
JP5695200B2 (ja) * 2010-09-10 2015-04-01 ハンジョウ ベンシェン ファーマシューティカル シーオー．， エルティーディー．Ｈａｎｇｚｈｏｕ Ｂｅｎｓｈｅｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． 複素環アミノベルバミン誘導体、その調製方法及び使用
BR112013011868A2 (pt) * 2010-11-16 2016-08-23 Acetylon Pharmaceuticals Inc compostos de pirimidina hidróxi amida como inibidores da proteína desacetilase, composição farmacêutica e uso dos referidos compostos
EP2651417B1 (en) 2010-12-16 2016-11-30 Calchan Limited Ask1 inhibiting pyrrolopyrimidine derivatives
US9708299B2 (en) 2011-01-03 2017-07-18 Genentech, Inc. Hedgehog antagonists having zinc binding moieties
CA2825825A1 (en) * 2011-01-27 2012-08-02 The Trustees Of Princeton University Inhibitors of mtor kinase as anti-viral agents
WO2012118978A1 (en) * 2011-03-03 2012-09-07 The Regents Of The University Of Colorado, A Body Corporate Methods for treating oncovirus positive cancers
DK3111938T3 (da) 2011-04-01 2019-07-01 Curis Inc Phosphoinositid 3-kinase-hæmmer med en zink-bindende gruppe
US20130102595A1 (en) * 2011-04-15 2013-04-25 Curis, Inc. Treatment of cancers having k-ras mutations
EP2524918A1 (en) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines derivates as kinase inhibitors
ES2575143T3 (es) * 2011-11-23 2016-06-24 Cancer Research Technology Limited Inhibidores de tienopiridina de la proteína quinasa C atípica
EP3010586A1 (en) 2013-06-21 2016-04-27 Lupin Limited Substituted heterocyclic compounds as crac modulators
US9790231B2 (en) 2013-06-24 2017-10-17 Lupin Limited Chromane and chromene derivatives and their use as CRAC modulators
CN105764501A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群治疗效益的组合物
ES2929576T3 (es) 2013-10-08 2022-11-30 Acetylon Pharmaceuticals Inc Combinaciones de inhibidores de histona deacetilasa 6 y el inhibidor de Her2 lapatinib para el uso en el tratamiento del cáncer de mama
WO2015054474A1 (en) 2013-10-10 2015-04-16 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors
US10660890B2 (en) 2013-10-24 2020-05-26 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr) Treatment of polycystic diseases with an HDAC6 inhibitor
CR20160308A (es) 2013-12-03 2016-11-08 Acetylon Pharmaceuticals Inc Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
CN104725301A (zh) * 2013-12-20 2015-06-24 北京蓝贝望生物医药科技股份有限公司 一种1,2-二氢吡啶-2-酮衍生物的制备方法
US9464073B2 (en) 2014-02-26 2016-10-11 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors
SG11201700094TA (en) 2014-07-07 2017-02-27 Acetylon Pharmaceuticals Inc Treatment of leukemia with histone deacetylase inhibitors
HRP20220522T1 (hr) 2014-08-04 2022-06-10 Nuevolution A/S Proizvoljno kondenzirani heterociklil-supstituirani derivati pirimidina koji su korisni za liječenje upalnih, metaboličkih, onkoloških i autoimunih bolesti
CN104292242B (zh) * 2014-09-18 2017-05-17 广州必贝特医药技术有限公司 噻吩嘧啶类化合物和制剂及其制备方法和应用
US9937174B2 (en) 2014-12-05 2018-04-10 University of Modena and Reggio Emilia Combinations of histone deacetylase inhibitors and bendamustine
HRP20192041T1 (hr) * 2014-12-11 2020-02-07 Natco Pharma Limited [derivati 7-(morfolinil)-2-(n-piperazinil) metil tieno [2, 3-c]piridina kao lijekovi protiv raka]
US10227347B2 (en) 2015-04-21 2019-03-12 Guizhou Bailing Group Pharmaceutical Co., Ltd. Purinyl-N-hydroxyl pyrimidine formamide derivative, preparation methods and uses thereof
US10272084B2 (en) 2015-06-01 2019-04-30 Regenacy Pharmaceuticals, Llc Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy
CN105037345B (zh) * 2015-06-09 2019-01-25 天津渤海职业技术学院 抗肿瘤化合物、其制备方法和用途
EP3380476B1 (en) * 2015-11-23 2020-09-30 Council of Scientific and Industrial Research Fused pyrimidines as isoform selective phosphoinositide-3-kinase-alpha inhibitors and process for preparation thereof
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
EP3445364A4 (en) 2016-04-19 2019-11-27 Acetylon Pharmaceuticals, Inc. HDAC INHIBITORS, ONLY OR IN COMBINATION WITH BTK INHIBITORS, FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
TW201811795A (zh) 2016-08-24 2018-04-01 美商亞闊股份有限公司 胺基－吡咯并嘧啶酮化合物及其用途
WO2018085342A1 (en) * 2016-11-02 2018-05-11 Curis, Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
MX387203B (es) * 2016-11-18 2025-03-18 Cystic Fibrosis Found Pirrolopirimidinas como potenciadores de cftr.
JP7595413B2 (ja) 2016-11-30 2024-12-06 ケース ウエスタン リザーブ ユニバーシティ １５－ｐｇｄｈ阻害剤とコルチコステロイドおよび／またはｔｎｆ阻害剤との組み合わせならびにその使用
WO2018145080A1 (en) 2017-02-06 2018-08-09 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
CN108623491B (zh) * 2017-03-24 2020-12-22 联化科技股份有限公司 一种卤代苯甲酰胺化合物的制备方法
CN107163061A (zh) * 2017-04-14 2017-09-15 江西科技师范大学 含吡唑啉结构的噻吩并嘧啶类化合物的制备及应用
SG11202102343QA (en) 2018-09-11 2021-04-29 Curis Inc Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
CN120463721A (zh) 2018-11-21 2025-08-12 卡斯西部储备大学 调节短链脱氢酶活性的组合物和方法
KR20210124310A (ko) * 2019-02-06 2021-10-14 벤테라, 인코포레이티드 국소 포스포이노시티드 3-키나제 억제제
PY2062546A (es) 2019-10-09 2021-09-13 Biocryst Pharm Inc Inhibidores del factor d del complemento para administración oral
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
US11685727B2 (en) 2019-12-20 2023-06-27 Nuevolution A/S Compounds active towards nuclear receptors
CA3174176A1 (en) 2020-03-31 2021-10-07 Sanne Schroder Glad Compounds active towards nuclear receptors
EP4126874A1 (en) 2020-03-31 2023-02-08 Nuevolution A/S Compounds active towards nuclear receptors
WO2022152229A1 (zh) * 2021-01-15 2022-07-21 深圳微芯生物科技股份有限公司 一类吗啉衍生物及其制备方法和应用
JP7736782B2 (ja) * 2021-03-29 2025-09-09 株式会社カネカ （２－メチルピリミジン－５－イル）ボロン酸誘導体の製造方法
CN113754680B (zh) * 2021-09-28 2022-07-22 云白药征武科技(上海)有限公司 一种α氟代酰基哌嗪衍生物及其制备和应用
US20250042914A1 (en) * 2021-09-30 2025-02-06 Hanmi Pharm. Co., Ltd. Pikfyve kinase inhibitor
UY40234A (es) 2022-04-22 2023-11-15 Vertex Pharma Compuestos heteroarilo para el tratamiento del dolor
CN117865979A (zh) * 2024-01-04 2024-04-12 广州必贝特医药股份有限公司 噻吩嘧啶类化合物的晶型及其制备方法
CN119161359B (zh) * 2024-09-18 2026-03-20 辽宁大学 一种新型含丙烯酰胺结构的4-吗啉基噻吩并[3,2-d]嘧啶类化合物及其应用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5502187A (en) * 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
WO2000022551A1 (en) * 1998-10-13 2000-04-20 Chris Cheah Method and system for controlled distribution of information over a network
CN1186324C (zh) 2000-04-27 2005-01-26 山之内制药株式会社 稠合杂芳基衍生物
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
ES2306859T3 (es) 2002-03-13 2008-11-16 Janssen Pharmaceutica Nv Derivados de sulfonil como nuevos inhibidores de histona deacetilasa.
DE60326436D1 (en) 2002-03-13 2009-04-16 Janssen Pharmaceutica Nv Aminoderivate als histone-deacetylase-inhibitoren
OA12793A (en) 2002-03-13 2006-07-10 Janssen Pharmaceutica Nv Sulfonylamino-derivatives as novel inhibitors of histone deacetylase.
MXPA04008796A (es) 2002-03-13 2004-11-26 Janssen Pharmaceutica Nv Derivados de carbonilamino como novedosos inhibidores de desacetilasa de histona.
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
US7300935B2 (en) * 2003-01-29 2007-11-27 Takeda Pharmaceutical Company Thienopyrimidine compounds and use thereof
WO2005117909A2 (en) * 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
US7218492B2 (en) * 2004-09-17 2007-05-15 Electronic Polymers, Inc. Devices and systems for electrostatic discharge suppression
EP1806347A4 (en) 2004-10-08 2009-07-01 Astellas Pharma Inc PYRIMIDINE DERIVATIVES FUSED WITH AN AROMATIC RING
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
NZ589276A (en) 2005-02-03 2012-06-29 Topotarget Uk Ltd Combination therapies using hdac inhibitors and erlotinib (tarceva)
AU2006248938B2 (en) 2005-05-18 2011-09-29 Janssen Pharmaceutica N.V. Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
US7731753B2 (en) * 2005-09-01 2010-06-08 Spinal Kinetics, Inc. Prosthetic intervertebral discs
JP5021660B2 (ja) * 2005-10-24 2012-09-12 バイオメット・３アイ・エルエルシー 歯科用インプラント構成要素を製造するための方法
JP2007151829A (ja) * 2005-12-05 2007-06-21 Bridgestone Sports Co Ltd ゴルフクラブヘッド
WO2007082880A1 (en) 2006-01-19 2007-07-26 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
US7834011B2 (en) 2006-01-19 2010-11-16 Janssen Pharmaceutica N.V. Heterocyclylalkyl derivatives as novel inhibitors of histone deacetylase
AU2007206942B2 (en) 2006-01-19 2012-08-23 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
RU2008141356A (ru) 2006-04-26 2010-06-10 Ф. Хоффманн-Ля Рош Аг (Ch) Производные пиримидина в качестве ингибиторов фосфатидилинозитол-3-киназы (pi3k)
TWI498332B (zh) * 2006-04-26 2015-09-01 Hoffmann La Roche 作為pi3k抑制劑之嘧啶衍生物及相關製備方法、醫藥組合物、用途、套組及產物
CN101511840A (zh) * 2006-04-26 2009-08-19 吉宁特有限公司 磷酸肌醇3-激酶抑制剂化合物及其使用方法
MX2008013578A (es) 2006-04-26 2009-03-23 Hoffmann La Roche Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
WO2007131364A1 (en) 2006-05-16 2007-11-22 Mcgill University Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties
AU2007296743B2 (en) 2006-09-11 2012-02-16 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
CN101535279B (zh) * 2006-09-11 2015-05-20 柯瑞斯公司 含锌结合基的喹唑啉基egfr抑制剂
AU2007296745B2 (en) * 2006-09-11 2011-12-01 Curis, Inc. Quinazoline based EGFR inhibitors
US20080161320A1 (en) 2006-09-11 2008-07-03 Xiong Cai Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
WO2008033744A2 (en) * 2006-09-11 2008-03-20 Curis, Inc. Dna methyl transferase inhibitors containing a zinc binding moiety
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
CA2663147A1 (en) 2006-09-11 2008-03-20 Curis, Inc. Substituted 2-indolinone as ptk inhibitors containing a zinc binding moiety
EP2061772A4 (en) 2006-09-11 2011-06-29 Curis Inc MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES
CN101573333B (zh) 2006-10-28 2013-06-12 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
WO2008070740A1 (en) * 2006-12-07 2008-06-12 F.Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and methods of use
ES2571028T3 (es) 2006-12-07 2016-05-23 Genentech Inc Compuestos inhibidores de fosfoinositida 3-cinasa y métodos de uso
BRPI0807812A2 (pt) 2007-02-15 2020-06-23 Novartis Ag Combinações de lbh589 com outros agentes terapêuticos para tratar câncer
EP2136809A4 (en) 2007-03-20 2012-01-04 Curis Inc INHIBITORS OF RAF KINASE CONTAINING A ZINC BINDING FRAGMENT
TW200922590A (en) 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety
WO2009036066A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
WO2009036057A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Antiproliferative agents containing a zinc binding moiety
WO2009036020A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Mek inhibitors containing a zinc binding moiety
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
AU2008298948B2 (en) 2007-09-12 2014-09-04 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
US8129371B2 (en) * 2007-10-16 2012-03-06 Wyeth Llc Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors
US8354528B2 (en) 2007-10-25 2013-01-15 Genentech, Inc. Process for making thienopyrimidine compounds
US20090149511A1 (en) 2007-10-30 2009-06-11 Syndax Pharmaceuticals, Inc. Administration of an Inhibitor of HDAC and an mTOR Inhibitor
WO2009086012A1 (en) 2007-12-20 2009-07-09 Curis, Inc. Aurora inhibitors containing a zinc binding moiety
WO2010008847A2 (en) 2008-06-24 2010-01-21 Takeda Pharmaceutical Company Limited Pi3k/m tor inhibitors
WO2009155659A1 (en) 2008-06-27 2009-12-30 The University Of Queensland Combination therapy
AU2010203512C1 (en) * 2009-01-08 2013-10-17 Curis, Inc. Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
CN102369011A (zh) 2009-03-12 2012-03-07 健泰科生物技术公司 用于治疗造血恶性肿瘤的磷酸肌醇3-激酶抑制剂化合物与化学治疗剂的组合
KR101489045B1 (ko) 2009-10-12 2015-02-02 에프. 호프만-라 로슈 아게 Ｐｉ3ｋ 억제자 및 ｍｅｋ 억제자의 조합
AU2011239537A1 (en) * 2010-04-16 2012-11-15 Curis, Inc. Treatment of cancers having K-ras mutations
DK3111938T3 (da) 2011-04-01 2019-07-01 Curis Inc Phosphoinositid 3-kinase-hæmmer med en zink-bindende gruppe
US20130102595A1 (en) 2011-04-15 2013-04-25 Curis, Inc. Treatment of cancers having k-ras mutations

Also Published As

Publication number Publication date
IL213976A0 (en) 2011-08-31
US20230227467A1 (en) 2023-07-20
US20120088764A1 (en) 2012-04-12
JP2012514650A (ja) 2012-06-28
DK2385832T3 (en) 2015-09-21
SG196815A1 (en) 2014-02-13
HRP20150947T1 (hr) 2015-10-09
US20150203509A1 (en) 2015-07-23
BRPI1004899A2 (pt) 2016-04-05
US8367663B2 (en) 2013-02-05
US9725461B2 (en) 2017-08-08
TW201030009A (en) 2010-08-16
PT2385832E (pt) 2015-11-02
RS54230B1 (sr) 2015-12-31
BRPI1004899B1 (pt) 2020-08-18
US20170362251A1 (en) 2017-12-21
US20200339593A1 (en) 2020-10-29
TWI558710B (zh) 2016-11-21
US20210214370A1 (en) 2021-07-15
SI2385832T1 (sl) 2015-10-30
EA024252B1 (ru) 2016-08-31
EP2385832B1 (en) 2015-07-15
US11597732B2 (en) 2023-03-07
JP5762520B2 (ja) 2015-08-12
SMT201500226B (it) 2015-10-30
KR20140094590A (ko) 2014-07-30
AU2010203512C1 (en) 2013-10-17
AU2010203512A1 (en) 2011-08-11
US20250230169A1 (en) 2025-07-17
SG172908A1 (en) 2011-08-29
US20220402934A1 (en) 2022-12-22
US10676482B2 (en) 2020-06-09
KR101430424B1 (ko) 2014-08-14
EP2385832A1 (en) 2011-11-16
US11261195B2 (en) 2022-03-01
MX2011007326A (es) 2011-10-19
EA201101053A1 (ru) 2012-02-28
KR20110112404A (ko) 2011-10-12
JP2015187145A (ja) 2015-10-29
US8461157B2 (en) 2013-06-11
JP2014058571A (ja) 2014-04-03
ES2550032T3 (es) 2015-11-04
BRPI1004899B8 (pt) 2021-05-25
WO2010080996A1 (en) 2010-07-15
CA2749228A1 (en) 2010-07-15
PL2385832T3 (pl) 2016-01-29
HK1164113A1 (en) 2012-09-21
HUE027615T2 (en) 2016-10-28
US8906909B2 (en) 2014-12-09
IL213976A (en) 2015-03-31
CY1116797T1 (el) 2018-03-07
CA2749228C (en) 2016-05-17
JP5452617B2 (ja) 2014-03-26
US20100222343A1 (en) 2010-09-02
CN102341108A (zh) 2012-02-01
US20140155595A1 (en) 2014-06-05
US10894795B2 (en) 2021-01-19
EP2385832A4 (en) 2012-07-25
CN102341108B (zh) 2015-05-27
US20190352310A1 (en) 2019-11-21
IL237727A0 (en) 2015-05-31
US10336770B2 (en) 2019-07-02
AU2010203512B2 (en) 2013-03-14

Similar Documents

Publication Publication Date Title
ME02230B (me) Inhibitori fosfoinozitid 3-kinaze sa delom koji vezuje cink
JP2010502744A5 (me)
JP2010502743A5 (me)
JP2010522163A5 (me)
JP2010502741A5 (me)
JP2010502742A5 (me)
TWI632348B (zh) Environmental light filtering circuit, optical sensor and photoelectric detecting device using same
JP2015182833A (ja) アシストスーツ
CN107662633A (zh) 置物篮及其婴儿车设备
CA2663147A1 (en) Substituted 2-indolinone as ptk inhibitors containing a zinc binding moiety
EP3057142A3 (en) Bi-directional reflective optical sensor module
JP2016536060A5 (me)
FI954300A7 (fi) Organismia koskevan tiedon mittauslaite ja rakenteeseen kiinnitettävän tyyppinen pulssiaaltojen mittauslaite
CN202406515U (zh) 一种钵盘集盘装置
PE20110804A1 (es) Compuestos novedosos como ligandos de receptores de cannabinoides
TW201313554A (zh) 具有接觸部件之前變速器
JP2011525482A5 (me)
EP3438550A3 (en) Shelf support device and cooking appliance with the same
CN102792813B (zh) 用于穴盘苗移栽的自动取喂苗机构
RU2012134446A (ru) Система позиционирования по меньшей мере одного гибкого трубчатого элемента, соединенного с чашеобразным элементом
JP2009518802A5 (me)
TR201718650T3 (tr) Bir taşıyıcı içeren bir çamaşır kurutucu.
CN106429183B (zh) 一种设有夹取机构的模板检测设备
JP2012192017A5 (me)
JP6274528B2 (ja) 苗移植機